find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
60
Clinical Trials
Lymphoma
NA
Active
nct/study# NCT04981795 / MOR208C414
Prospective Multicenter Observational Study Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Starting Second- Or Third-Line Therapy And Not Receiving Autologous Stem Cell Transplant (REAL-MIND)
Learn More
Lymphoma
N/A
Active
nct/study# NCT04982471 / NDS-DLBCL-003
Connect® Lymphoma Disease Registry: A Us-Based Prospective Observational Cohort Study
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT03033914 / MSK16-1536
Phase I/II Of Nivolumab And A(B)VD In The Front-Line Setting For High Risk Hodgkin Lymphoma
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03233347 / LY-1601
A Phase II Trial Of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, And Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With Or Without Brentuximab Vedotin Plus Nivolumab, Followed By Nivolumab Consolidation For Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NCT03711604 / RP6530-1803
An Open Label, Compassionate Use Study Of Tenalisib (RP6530) In Patients Currently Receiving Treatment On Tenalisib Trials In Hematological Malignancies
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT02628405 / RU051417I
Phase I/II, Open-Label Study Of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) In Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.